Fig. 3

Inhibition of DU-145-RFP-Luc xenograft growth by 6 MBq [¹⁷⁷Lu]Lu-DOTA-Miltuximab® in vivo. DU-145-RFP-Luc cells (5 × 10⁶) in Matrigel were injected subcutaneously into the right flank of BALB/c/nude mice. On day 34 post tumour cell inoculation, BALB/C/nude mice bearing DU-145-RFP-Luc xenografts were injected with DOTA-Miltuximab® (n = 6) or 6 MBq [¹⁷⁷Lu]Lu-DOTA-Miltuximab® (n = 6) intravenously. Mice were weighed and tumour volumes were measured twice weekly via callipers. a Average mouse body weight over time. b Percentage mouse body weight relative to start of the treatment. c Mean weekly mouse tumour volume. Day 53, *p = 0.0353; 55, *p = 0.0358; 58, *p = 0.0255; 62, *p = 0.0191. d Individual mouse tumour weights at endpoint. Data expressed as mean ± SEM and statistical analysis performed using an unpaired t test. *p < 0.05